Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) insider Daniel Lee Flynn sold 148,107 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $40.92, for a total transaction of $6,060,538.44. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of DCPH stock opened at $36.30 on Friday. The company has a 50 day moving average price of $23.11 and a 200-day moving average price of $24.33. Deciphera Pharmaceuticals Inc has a 52 week low of $18.55 and a 52 week high of $42.99. The firm has a market capitalization of $762.39 million, a PE ratio of -12.87 and a beta of 2.34. The company has a quick ratio of 7.26, a current ratio of 7.26 and a debt-to-equity ratio of 0.01.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.56. The company had revenue of $25.00 million during the quarter, compared to the consensus estimate of $20.00 million. Analysts anticipate that Deciphera Pharmaceuticals Inc will post -4.29 earnings per share for the current year.
A number of analysts have weighed in on DCPH shares. ValuEngine lowered shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Piper Jaffray Companies raised their price objective on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, June 3rd. They noted that the move was a valuation call. Canaccord Genuity restated a “buy” rating and set a $65.00 price objective (up from $50.00) on shares of Deciphera Pharmaceuticals in a research note on Wednesday. SunTrust Banks raised their price objective on shares of Deciphera Pharmaceuticals to $60.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, BidaskClub upgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Deciphera Pharmaceuticals has an average rating of “Buy” and an average target price of $47.90.
Several hedge funds have recently made changes to their positions in DCPH. Dimensional Fund Advisors LP acquired a new position in shares of Deciphera Pharmaceuticals during the fourth quarter worth $4,337,000. Geode Capital Management LLC lifted its holdings in shares of Deciphera Pharmaceuticals by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 166,904 shares of the company’s stock worth $3,503,000 after purchasing an additional 27,157 shares during the period. Bank of America Corp DE lifted its holdings in shares of Deciphera Pharmaceuticals by 1,506.1% during the fourth quarter. Bank of America Corp DE now owns 23,561 shares of the company’s stock worth $494,000 after purchasing an additional 22,094 shares during the period. Norges Bank acquired a new position in shares of Deciphera Pharmaceuticals during the fourth quarter worth $6,974,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of Deciphera Pharmaceuticals by 61,033.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after purchasing an additional 1,831 shares during the period. Hedge funds and other institutional investors own 59.10% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Article: What are the reasons investors use put options?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.